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ABSTRACT- 
Background: The use of antihypertensive medication and hypertension control have 
significantly increased over recent decades in some developed countries, but the impact of 
improved drug treatment on blood pressure (BP) control in the population is unknown.  
Methods and Results: Data were taken from two surveys representative of the population 
aged ≥60 years in Spain conducted with the same methodology in 2000-2001 and in 2008-
2010. BP was measured six times. The first BP reading was discarded, and the average of 
the remaining 3 to 5 BP readings was taken for analysis. Hypertension prevalence was 
68.7% in 2000-2001 and 66.0% in 2008-2010. Between both time periods there was an 
improvement in hypertension awareness (63.6% through 67.7%), drug treatment among 
those aware (84.5% through 87.5%), and BP control among treated hypertensives (30.3% 
through 42.9%). Overall, BP control among all hypertensives increased from 16.3% to 
25.4%. After adjustment for age, sex, education, hypertension duration, smoking, alcohol 
consumption, body mass index, sedentary behavior, diabetes, cardiovascular disease, and 
visits to the physician through logistic regression, about 7% of the improvement in BP 
control among all hypertensives was explained by higher hypertension awareness, and 
36.2% was explained by a higher treatment rate. Among the treated hypertensives, 22.6% of 
the progress in BP control was due to the increase in the number of BP medications used in 
each patient. 
Conclusions: BP control among the older hypertensive population in Spain has improved 
from 2000-2001 to 2008-2010 due to a higher treatment rate and more intense 
antihypertensive drug treatment.  
 
Key Words: hypertension; treatment; population studies; epidemiology; aging  
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Hypertension is an important public health challenge because it is highly prevalent in many 
developed and developing countries.
1,2 
As a result, high blood pressure (BP) is the leading 
risk factor for global disease burden, accounting for 7.6 million premature deaths and 7% of 
disability-adjusted life years worldwide.
3 
Moreover, in spite of proved benefits of treating 
hypertension and availability of abundant guidelines for managing hypertension,
4-7 
BP 
control in the population is only moderate.
2,4,5,7
 
Several studies have shown that in some countries the prevalence of hypertension has been 
generally stable and that a significant improvement in hypertension management has 
occurred over the last few decades.
8-15 
However, some studies have found no recent progress 
in BP control,
16,17 
and it has been questioned whether a favourable trend is actually 
occurring in the population.
18 
Discrepancies in results among studies might be partly due to 
the use of different settings and procedures for BP measurement. Appropriate trend analyses 
require that: (i) BP measurement is accurate, including minimizing the office or white-coat 
effect,
19,20
 and (ii) the results of clinic-based studies are considered separately from those of 
population-based research. In fact, participation in clinic-based studies is probably 
associated with health status and service accessibility, which are in turn related to the 
likelihood of being diagnosed with hypertension, of receiving drug treatment and achieving 
BP control. Thus, clinical surveys mainly serve to monitor the effectiveness of BP control in 
the clinic, and population-based studies are required to assess BP control in the general 
population. 
Although the use of antihypertensive medication and BP control have significantly increased 
in some countries over recent decades,
9,11-14,21
 to our knowledge no attempts have been made 
to assess the independent impact of healthcare variables that influence BP control 
(awareness, treatment, and number of medications) on the changes in BP control over time.  
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We have used two comparable national population-based surveys in Spain, that included a 
series of BP measurements taken in relaxed conditions at subjects´ home,
22,23
 to get a 
reliable picture of the clinical epidemiology of hypertension during the first decade of the 
XXI century. Specifically, we have estimated the independent contribution of awareness, 
drug treatment, and number of BP medications to the observed trends in the control of 
hypertension. Due to data availability, we have focused on the older adult population, where 
hypertension is very frequent but BP control is difficult to achieve.
4-7,24
 
Methods 
Study design and participants 
We have analyzed data from two studies conducted with the same methodology. The first 
one was carried out in 2000-2001 among 4009 individuals representative of the non-
institutionalized population aged ≥60 years in Spain.22 The second study was conducted 
between 2008 and 2010 on a representative sample of 12948 people aged ≥18 years,23,25 
which included 3488 individuals aged ≥60 years. Response rate among these older 
individuals was 70% and 60% in the first and second study, respectively. In both studies, 
subjects were selected through census-based multistage cluster random sampling. The 
information was collected by trained observers, through personal interview using structured 
questionnaires followed by physical examination (BP and anthropometric variables) at 
subjects´ home. 
Participants gave written consent and both studies were approved by the clinical research 
ethics committees of the Hospital Universitario “La Paz” in Madrid and the Hospital 
“Clínic” in Barcelona.  
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Study variables 
Study participants reported their age, sex, level of education, hypertension duration (time 
since hypertension diagnosis by a physician), tobacco and alcohol consumption, sedentary 
behavior, history of diagnosed diabetes and cardiovascular disease (coronary heart disease 
and stroke), and use of healthcare services (annual number of any visit to the physician). 
Sedentary behavior was estimated with a standard questionnaire that asks about the number 
of hours spent watching television, seated in transportation, reading, listening to the music 
or using the computer, over a typical week, and was defined arbitrarily as ≥37 hours per 
week (percentile 65th in the 2000-1survey and 70th in the 2008-10 survey).  
In both surveys, BP was measured by trained observers using standardized procedures,
19,26
 
with validated automatic devices (Omron 706/711 in 2000-2001 and Omron M6 in 2008-
2010) and cuffs of three sizes according to arm circumference. In each survey, two sets of 
BP readings were obtained separated by a minimum of 90 minutes. In each set, BP was 
measured three times at 1-2 minute intervals, after resting 3-5 minutes in a seated position. 
The first BP reading was discarded, and the average of the remaining 3 to 5 BP readings was 
taken for analysis (mean number of BP readings was 4.69 in 2000 and 4.96 in 2010). 
Hypertension was defined as systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 
mmHg and/or on current antihypertensive drug treatment. Hypertension awareness was 
deemed as an affirmative answer to the question: “Have you ever been told by the doctor 
that you had hypertension?” Treatment was defined as reported current use of prescribed 
hypertension drug therapy. Finally, BP control was defined as pharmacological treatment of 
hypertension associated with SBP<140 mmHg and DBP <90 mmHg, which were the BP 
goals at the time of the surveys analyzed.  
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Weight and height were measured in each subject under standardized conditions.
25 
Body 
mass index (BMI) was calculated as weight in kg divided by squared height in m. Obesity 
was defined as BMI ≥30 kg/m2.  
Medication use was collected by a face-to-face interview and verified against drug 
packaging during the home visit in both surveys. Antihypertensive medications were 
classified according to international guidelines.
26
 
Statistical analysis 
Of the 4009 study participants in 2000-2001 and 3488 in 2008-2010, 429 and 214, 
respectively, were excluded due to lack of data on BP or demographic variables. Thus, 3580 
individuals in 2000 and 3273 in 2010 were available for analysis. We calculated the 
prevalence of hypertension as well as of awareness, treatment, and control in each survey, 
and their relative change between surveys ([(proportion in 2010)–(proportion in 2000)] x 
100 / (proportion in 2000)]), stratified by sociodemographic and clinical characteristics. The 
analyses took account of the complex sampling design; thus, individual observations were 
weighted to reconstruct the Spanish population, and the variances were corrected to obtain 
appropriate confidence intervals. The chi-square test was used to compare proportions and 
the Student t-test to compare means.  
In order to analyze the factors contributing to the time trend in hypertension control, we first 
created a new variable called “time of survey” (T), which takes value 0 if 2000-2001 and 
value 1 if 2008-2010. Second, databases from the 2000-2001 and 2008-2010 surveys were 
merged, and only hypertensive patients were selected. Third, two multiple logistic 
regression models were built, in which the outcome or dependent variable was: (i) control of 
BP (yes/no) among all hypertensive patients, and (ii) control of BP (yes/no) among treated 
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hypertensive patients. Year 2000-1 was used as the reference category. Main independent 
variables were T, sociodemographic characteristics, cardiovascular risk factors, and use of 
healthcare services, which might be relevant for hypertension control
4-7 
and were selected a 
priori. The sociodemographic characteristics included age, sex, and educational level, while 
the cardiovascular risk factors included hypertension duration, BMI, sedentary behavior, 
smoking, alcohol consumption, diabetes, and cardiovascular disease (CVD). The odds ratio 
(OR) of T measures whether BP control has improved between both surveys after adjusting 
for those characteristics. Healthcare variables influencing BP control (awareness, drug 
treatment, and number of BP medications) were added sequentially to the models. 
Specifically, the first model, run on 4076 hypertensives (88.2% of all the hypertensive 
patients), was additionally adjusted for hypertension awareness and antihypertensive drug 
treatment; and the second model, run on 2264 treated hypertensives (87.1% of the treated 
hypertensive patients), was additionally adjusted for the number of BP medications since all 
patients were aware and treated. The change in the OR of T measures the independent 
contribution of each of these healthcare variables to the change in hypertension control 
between the two surveys, and was calculated using the formula: [OR(fully adjusted except for the 
specific healthcare variable) – OR(fully adjusted model)]x 100/[OR(fully adjusted except for the specific healthcare variable)– 
1].
27 
Variables were modelled as categorical (dichotomic) except age, hypertension duration, 
BMI, and number of BP medications (continuous). The analyses were conducted in the total 
study sample and separately by sex. Statistical significance was set at 2-sided p <0.05. 
Analyses were performed with the SPSS package v. 21.0.  
 
Results 
CIRCCQO/2014/001191 
 
 
 8 
Change in hypertension prevalence 
The prevalence of hypertension decreased from 68.7% in 2000-2001 to 66.0% in 2008-2010 
(Table 1).This reduction occurred specifically among individuals under age 80, women, 
with lower education, and absence of diabetes or obesity.  
Change in hypertension awareness, treatment, and control 
Awareness of hypertension and drug treatment among the aware hypertensives increased 
slightly between 2000-2001 and 2008-2010 (63.6% through 67.7%, and 84.5% through 
87.5%, respectively) (Table 2). Thus, drug treatment among all hypertensive patients 
increased from 53.7% in 2000-2001 to 59.2% in 2008-2010. Moreover, a substantial 
improvement in BP control was found among treated hypertensives (30.3% through 42.9%). 
The improvement in awareness and drug treatment was greater in persons aged ≥70 years, 
men, with lower education, with diabetes or obesity, and without sedentary behavior. 
However, the improvement in BP control among treated hypertensives was more frequent 
among patients under age 80, men, with higher education, without obesity, or sedentary 
behavior (Table 2).  
Overall, BP control among all hypertensive patients increased from 16.3% in 2000-2001 to 
25.4% in 2008-2010, an improvement that was higher in patients under age 80, men, with 
higher education, diabetes, without obesity or sedentary behavior, and in those on less than 3 
drugs (Table 3).  
Factors contributing to change in blood pressure control 
Table 4 shows the time changes in variables which could potentially influence the change in 
BP control among hypertensive patients. Mean age was somewhat lower in 2008-2010 than 
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in 2000-2001 (69.9 and 72.1 years, respectively). The percentage of hypertensives with 
≤primary education fell from 87.7% to 60.0%. Both mean SBP and mean DBP decreased 
significantly (2.9 mmHg and 1.7 mmHg, respectively). Moreover, sedentary behavior 
became less frequent, and a significant reduction was seen in the frequency of previous 
CVD. The percentage of current smokers increased slightly (among women) as well as the 
percentage of current alcohol drinkers. Lastly, the number of antihypertensive drugs 
increased between 2000-2001 and 2008-2010 (1.4 to 1.8), and the percentage on 
combination therapy increased from 40.9% to 48.6% relying heavily on those on 3 or more 
medications (9.6% to 15.6%). 
Logistic regression analyses show that the odds of BP control among all hypertensive 
patients was 1.75 times greater in 2008-2010 than in 2000-2001, and it was still 1.74 times 
higher after adjusting for socio-demographic variables, cardiovascular risk factors, and use 
of healthcare services (Table 5). That is, a real improvement in BP control has occurred 
between both time periods, regardless of those important BP-related variables. After 
additional adjustment for hypertension awareness, the OR was 1.69; in relative terms, a 
6.8% lower than before adjustment. Thus, awareness of hypertension contributed, though to 
a moderate extent, to the increase in BP control over time. Lastly, additional adjustment for 
antihypertensive drug treatment used yielded an OR of 1.44. Thus, 36.2% of the 
improvement in BP control was explained by drug treatment beyond what is explained by 
awareness and the rest of variables (Table 5). Taken together, awareness and treatment 
explained 40.5% of the change observed in BP control. Separate models for men and women 
showed that the contribution of hypertension awareness and drug treatment to the 
improvement in BP control was higher among women (Table 5).  
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Among treated hypertensive patients, the OR of BP control was 1.62 after adjusting for 
sociodemographic and clinical variables (Table 6); additional adjusted for the number of BP 
medications led to and OR of 1.48. Thus, the increase in the number of BP medications 
between 2000-2001 and 2008-2010 explained 22.6% of the improvement in BP control, 
beyond what was accounted for sociodemographic and clinical variables. The influence of 
the number of antihypertensive drugs was somewhat higher among women (23.6% vs. 
19.0% in men).  
Discussion 
To our knowledge, this is the first study to systematically examine the impact of 
hypertension awareness and treatment on the time trends in BP control among older 
hypertensive patients from the general population. Our results show that the degree of BP 
control in hypertensive individuals improved significantly from 2000-2001 to 2008-2010, 
and that a substantial part of the improvement was due to a greater treatment rate and to an 
increase in the number of BP medications used in each patient.  
Comparison with other studies 
Previous reports in many countries have shown a high prevalence of hypertension, 
particularly in older age groups, and generally stable or modest reductions in hypertension 
prevalence in the last few decades.
2,8,9-14,16 
In our study, both the prevalence and mean SBP 
and DBP fell over time, which is consistent with a recent pooled analysis showing a 
worldwide reduction in SBP since 1980.
28
 The decrease in the prevalence of hypertension in 
Spain occurred selectively among women, probably related to the reduction in BMI recently 
observed in older women but not older men.
29
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As in most other countries, awareness, treatment and control of hypertension have generally 
increased in hypertensive patients, though the success rates achieved varied by country and 
sociodemographic and clinical subgroups.
9,11-15
.  
Control of hypertension among treated hypertensive patients improved by 13% in absolute 
terms (from 30% in 2000-2001 to 43% in 2008-2010). However, hypertension control is still 
far from the rates in a few other countries, like England (41% in 2003 and 50% in 2006 for 
treated hypertensive patients ≥65 years),9 the United States (47% in 2001-2 and 58% in 
2007-8 for treated hypertensive patients older than 60) and especially, Canada, where the 
control rate among treated patients was 64% in 2009.
12,13,16 
Nevertheless, hypertension 
control among both those treated and all hypertensives in Spain was comparable to or even 
higher than in many other countries.
10,11,14,15,30
 
Explanations for changes in hypertension control 
This study confirms the important role of drug treatment in BP control,
4-7
 and extends 
previous reports by quantifying the impact of increased awareness, treatment, and the 
number of BP medications. The higher contribution of awareness and treatment of 
hypertension to the improvement in BP control over time among women than men is 
consistent with their more favorable trend in SBP (absolute change -3.7 mmHg vs. -2.1 
mmHg in men), sedentary behavior (-12% vs. -1%), diabetes (-3.6% vs. +2.1%), and 
combined therapy (+8.8% vs. +5.9%).  
There is also evidence in some countries of a significant increase in the proportion of 
hypertensives taking multiple antihypertensive agents,
9,21,31,32 
in consonance with guidelines 
indicating that at least 2 antihypertensive agents are usually needed to achieve BP goals.
4-7 
However, no previous quantification of the impact of medication on time changes in BP 
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control has been made. Interestingly, the greater increase in polytherapy among hypertensive 
patients aged ≥60 years in the United States21 than in Spain during approximately the same 
time period (44.5% in 2000-2001 to 56.1% in 2009-2010 vs. 40.9% to 48.6%, respectively) 
was accompanied by a higher increase in BP control among treated patients in the United 
States (37.5% to 55.8%) than in Spain (30.3% to 42.9%).  
Intensification of drug treatment has been associated with a reduction of cardiovascular risk 
in habitual clinical practice.
33
 However, in Spain and the United States, physicians failed to 
increase medications in most uncontrolled hypertensive patients, especially in the 
elderly.
34,35 
Reluctance to initiate combination therapy in older patients was often because of 
safety concerns such as orthostatic hypotension.
4-7 
Also, as reported in the United States,
32 
we found that the proportion of treated uncontrolled patients taking 1 to 2 medications (a 
proxy for treatment inertia in our study)fell from 89.3% in 2000-2001to 81.9% in 2008-
2010, and the proportion on ≥3 medications (a proxy for apparent treatment-resistant 
hypertension) rose from 10.6% in 2000 to 18.1% in 2010 (data not presented).  
Overall, we were able to identify factors that accounted for less than 50% of the 
improvement in BP control in Spain over the last decade. The remainder, however, should 
still be elucidated. We have no data on trends in the salt content in food or sodium excreted 
in urine over time, but as in other countries,
36
 high levels are observed currently in Spain.
37
 
Moreover, the diet of hypertensive patients in Spain, including older individuals, has a low 
accordance with the DASH and Mediterranean dietary pattern, including sodium intake,
37
 
which may be counterbalancing efforts in drug treatment. Also, we did not study the 
potential effect of trends in advice and adherence to healthy lifestyle on BP control.  
Methodological aspects  
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Although the response rate in the Spanish surveys was somewhat lower than in the 
NHANES surveys in the United States,
38
 it was among the highest of the examination 
surveys conducted in Europe.
9,39 
Moreover, the sex, age, and educational level structure of 
the national surveys closely resemble the sociodemographic distribution of the Spanish 
population.
22,25
 
As regards variable measurement, six BP readings were made by trained lay personnel at 
subjects´ household, and the first measurement was excluded for analysis; all this 
contributes to reducing the alerting reaction. Also, the increase in BP control in Spain in the 
last decade was consistent with that reported in a series of primary-care surveys across the 
country.
31 
In addition, medication packages were checked at subjects´ home, which 
contributes to the accuracy of data in drug treatment. Unfortunately, medication dose and 
adherence were not assessed.  
We made an additional sensitivity analysis using the recently proposed clinic BP goal of 
150/90 mmHg for older people.
40
 As expected, BP control among treated hypertensives was 
much better when using the 150/90 threshold in both time periods (49.7% in 2000 and 
63.9% in 2010). Also, the percent contribution of the number of BP medications to the 
improvement in BP control between 2000 and 2010 was 15.9% (vs. 22.6% using the 140/90 
threshold). Thus, proportions of hypertension control and contribution of the number of BP 
medications were sensitive to the BP threshold, though the message of progress in BP 
control and the importance of more intense use of drug treatment remain.   
Proportions of prevalence and management of hypertension were presented stratified by age 
and clinical characteristics rather than adjusted, nevertheless age-adjusted proportions 
remained very similar (data not shown).  
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Given that the number of missing data for univariate and multivariable analyses was not 
high (<10% and <15%, respectively), and that there were no significant differences between 
persons with missing data and those without for most important variables (data not shown), 
we think bias due to excluded cases should not be relevant. However, there still may be bias 
due to unmeasured factors. Regarding the multivariable analyses, we adjusted for BP-related 
lifestyles and other important cardiovascular risk factors, thus isolating to some extent the 
independent effect of drug treatment on changes in BP control. Finally, the extrapolation to 
other countries with higher or lower values of the variables studied should be done with 
caution. Nevertheless, there is no reason to doubt that the same factors are influencing trends 
in different countries, though the relative contribution of each one could vary. 
Conclusions and implications  
Among older adults in Spain, BP control has increased during the last decade, and it was 
partly due to higher treatment rates and more intense drug treatment. However, despite 
progress, in 2008-2010 about one-third of hypertensive patients were still unaware of their 
hypertensive status, 40% were untreated, and more than half of treated patients were 
uncontrolled; as a result, only one in four patients achieved BP targets. Our results remark 
the importance of renewed efforts aiming at even higher and more intense use of drug 
treatments for achieving hypertension control in the general older population.  
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TABLE 1.Prevalence of Hypertension in Individuals Aged ≥60 years in Spain in 2000-2001 
and 2008-2010. 
CVD: Cardiovascular disease. For definition of variables see Methods.  Difference between number of 
subjects by risk factor strata and number of total individuals is due to missing data.  Relative change: 
[(proportion in 2010)–(proportion in 2000)] x 100 / (proportion in 2000). *p<0.05 between 2000-2001 and 
2008-20010.   
 2000-01  
 
2008-10  
 
2000-01  
 
2008-10  
 
 
 N N % % Relative change (%) 
Total 2461/3580 2162/3273 68.7 66.0* -3.9 
Age      
60-69 years 1038/1609 1169/1879 64.5 62.2* -3.6 
70-79 years 956/1315 791/1122 72.7 70.5* -3.0 
≥80 years 467/656 202/272 71.2 74.3* 4.3 
Sex      
Men 1059/1585 1012/1491 66.8 67.9* 1.6 
Women 1402/1995 1148/1783 70.3 64.4* -8.4 
Education      
≤Primary studies 2064/2979 1294/1932 69.3 67.0* -3.3 
≥Secondary studies 291/453 863/1332 64.2 64.8* 0.9 
Obesity      
No 1377/2103 1298/2132 65.5 60.9* -7.0 
Yes 910/1221 828/1092 74.5 75.8 1.7 
Sedentary behavior      
No 1461/2184 1440/2198 66.9 65.5* -2.1 
Yes 852/1161 626/899 73.4 69.6* -5.2 
Diabetes mellitus      
No 1877/2818 1680/2638 66.6 63.7* -4.4 
Yes 555/717 487/626 77.4 77.8 0.5 
Current smoking       
No 2217/3213 1918/2876 69.0 66.7* -3.3 
Yes 239/363 239/388 65.8 61.6* -6.4 
Current alcohol intake      
No 1570/2217 829/1247 70.8 66.5* -6.1 
Yes 890/1361 1294/1975 65.4 65.5 0.2 
Previous CVD      
No 2227/3256 2096/3176 68.4 66.0* -3.5 
Yes 224/307 63/89 73.0 70.8* -3.0 
Annual visits to the physician      
≤1 448/738 420/752 60.7 55.9* -7.9 
≥2 1998/2822 1736/2505 70.8 69.3 -2.1 
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TABLE 2. Awareness, Drug Treatment, and Control of Hypertension in Hypertensive Patients Aged ≥60 years in Spain in 2000-2001  
and 2008-2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVD: cardiovascular disease. % change: [(proportion in 2010)–(proportion in 2000)] x 100 / (proportion in 2000).. *p<0.05 between 2000-01 and 2008-10.  
 Awareness  Treatment among those aware  Control among those treated 
2000-01 
 
% 
2008-10 
% 
 2000-01 
% 
2008-10 
% 
  2000-01 
% 
2008-10 
% 
 
N 1564 1461   1322 1278   401 549  
  % % change  % % % change   % % % change 
Total 63.6 67.7* 6.4  84.5 87.5* 3.6  30.3 42.9* 41.6 
Age            
60-69 years 64.5 65.3 1.2  84.2 84.6 0.5  32.4 48.7* 50.3 
70-79 years 65.6 71.3* 8.7  83.9 90.6* 8.0  29.3 38.6* 31.7 
≥80 years 57.2 66.5* 16.3  86.9 91.0* 4.7  27.6 29.2 5.8 
Sex            
Men 58.8 64.2* 9.2  81.0 85.8* 5.9  27.6 42.7* 54.7 
Women 67.2 70.7* 5.2  86.8 88.8* 2.3  31.9 43.0* 34.8 
Education            
≤Primary studies 63.7 69.7* 9.4  84.3 88.7* 5.2  30.3 41.2* 36.0 
≥Secondary studies 59.8 64.5* 7.9  86.2 85.6 -0.7  29.3 45.8* 56.3 
Obesity            
No 58.7 62.7* 6.8  82.0 85.2* 3.9  29.7 44.6* 50.2 
Yes 68.8 74.9* 8.9  87.2 91.1* 4.5  31.6 40.8* 29.1 
Sedentary behavior            
No 62.3 67.2* 7.9  84.8 87.9* 3.7  30.0 44.4* 48.0 
Yes 65.1 69.3* 6.5  84.9 86.2 1.5  29.6 39.1* 32.1 
Diabetes mellitus            
No 61.2 64.8* 5.9  83.3 85.8* 3.0  31.8 45.3* 42.5 
Yes 71.7 77.5* 8.1  88.2 92.2* 4.5  26.2 37.5* 43.1 
Current smoking             
No  64.6 68.6* 6.2  84.8 88.0* 3.8  30.3 43.4* 43.2 
Yes 53.3 58.2* 9.2  82.0 83.5 1.8  30.5 38.3* 25.6 
Current alcohol intake            
No  64.0 71.1* 11.1  86.9 90.2* 3.8  29.6 39.5* 33.4 
Yes 62.8 65.6 4.5  80.5 85.6* 6.3  31.8 45.2* 42.1 
Previous CVD            
No 62.8 65.6* 4.5  80.5 85.6* 6.3  30.2 42.9* 42.1 
Yes 64.0 71.1* -11.1  86.9 90.2* 3.8  31.8 40.9* 28.6 
Annual visits to physician            
≤1  35.3 51.2* 45  73.4 73.5 0.1  31.0 42.8* 38.1 
≥2 69.7 71.6 2.7  86.1 89.9* 4.4*  30.3 42.9* 41.6 
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TABLE 3.Control of Hypertension Among All Hypertensive Patients Aged ≥60 years in 
Spain in 2000-2001 and 2008-2010. 
CVD: cardiovascular disease. BP: blood pressure. Control: systolic blood pressure <140 mmHg and 
diastolic blood pressure <90 mmHg in all individuals with hypertension. Relative change: [(proportion 
in 2010)–(proportion in 2000)] x 100 / (proportion in 2000). *p<0.05 between 2000-2001 and 2008-
2010. 
  
 
Year 2000-01 Year 2008-10  
N 2461 2162  
 % % Relative change (%) 
Total 16.3 25.4* 55.8 
Age    
60-69 years 17.6 27.0* 53.4 
70-79 years 16.1 24.9* 54.7 
≥80 years 13.7 17.3 26.3 
Sex    
Men 13.1 23.5* 79.4 
Women 18.6 26.9* 44.6 
Education    
≤Primary studies 16.3 25.5* 56.4 
≥Secondary studies 15.1 25.3* 67.5 
Obesity    
No 14.3 23.8* 66.4 
Yes 18.9 27.8* 47.1 
Sedentary behavior    
No 15.8 26.2* 65.8 
Yes 16.3 23.4* 43.6 
Diabetes mellitus    
No 16.2 25.2* 55.6 
Yes 16.6 26.9* 62.0 
Current smoking     
No 16.6 26.3* 58.4 
Yes 13.3 18.5 39.1 
Current alcohol intake    
No 16.4 25.2* 53.7 
Yes 16.1 25.4* 57.8 
Previous CVD    
No 15.3 24.1* 57.5 
Yes 17.7 26.5* 49.7 
Annual visits to the physician    
≤1/year 8.0 16.2* 102.5 
≥2/year 18.2 27.6* 51.6 
Number of BP medications    
None 0.4 0.3 -25.0 
One 22.1 34.8* 57.5 
Two  28.2 40.9* 45.0 
Three or more 29.1 39.1* 34.5 
CIRCCQO/2014/001191 
 
 
 25 
TABLE 4. Sociodemographic Characteristics, Cardiovascular Risk Factors and Treatment Among 
Hypertensive Patients Aged ≥60 years in Spain in 2000-2001 and 2008-2010. 
 Year 2000-2001 (N=2461)  Year 2008-2010 (N=2162) 
Characteristics  Mean±SD or % 95% CI  Mean±SD or % 95% CI 
Age (years) 72.1 ±7.7 71.8 to72.4  69.9 ±6.7 69.6 to70.2* 
Men 43.9 41.0 to 45.0  46.9 44.8 to 49.0 
Education (≤primary studies) 87.7 86.4 to 89.0  60.0 57.9 to 62.1* 
Blood pressure (systolic, mmHg) 150.9±18.0 150.2 to 151.6  148.0 ±18.2 147.2 to 148.7* 
Duration of hypertension (years) 5 (5-7) -  5 (4-8) - 
Body mass index (kg/m
2
) 29.2 ±4.7 29.0 to 29.4  29.2 ±4.4 29.0 to 29.4 
Sedentary behavior (≥37 h/week) 35.2 33.1 to 37.3  28.4 26.4 to 30.3* 
Diabetes mellitus  23.2 21.4 to 25.0  22.3 20.5 to 24.1 
Current tobacco smoking 9.7 8.5 to 10.9  11.1 9.8 to 12.4 
Current alcohol intake 36.2 34.2 to 38.2  61.6 59.5 to 63.7* 
Previous cardiovascular disease 9.1 8.0 to 10.2  2.9 2.2 to 3.6* 
Annual visits to the physician (≥2/year) 81.7 80.2 to 83.2  80.6 78.9 to 82.3 
#BP medication among treated patients 1.4 ±0.9 1.3 to 1.4  1.8 ±1.0 1.7 to 1.8* 
Combined therapy (≥2 drugs) 40.9 38.3 to 43.5  48.6 45.9 to 51.3* 
Three or more drugs 9.6 8.0 to 11.2  15.6 13.6 to 17.5* 
Hypertension duration is presented as median (P25-P75 interquartile range). For BP medication among treated patients, the 
appropriate N was 1322 in 2000 and 1278 in 2010. *p<0.05 between 2000-2001 and 2008-2010.  
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Table 5. Impact of Hypertension Awareness and Treatment on Change in Blood Pressure 
Control from 2000-2001 to 2008-2010 Among Hypertensive Patients Aged ≥60 years in Spain, 
by Sex. 
 
 Odds ratio 
(95% Confidence Interval) 
P value % of association explained 
by hypertension awareness 
and drug treatment* 
Total    
Crude model 1.75 (1.52 to 2.01) <0.001  
Models with progressive 
adjustment for: 
   
Sociodemographic variables 1.71(1.47 to 1.99) <0.001  
Cardiovascular risk factors 1.72 (1.45 to 2.04) <0.001  
Use of healthcare services 1.74 (1.47 to 2.06) <0.001  
Hypertension awareness 1.69 (1.41 to 2.02) <0.001 +6.8 
Antihypertensive drug treatment 1.44 (1.19 to 1.74) <0.001 +36.2 
    
Men    
Crude model 2.12 (1.67 to 2.69) <0.001  
Progressive adjustment for:    
Sociodemographic variables 1.90 (1.47 to 2.46) <0.001  
Cardiovascular risk factors 1.91 (1.44 to 2.53) <0.001  
Use of healthcare services  1.93 (1.45 to 2.55) <0.001  
Hypertension awareness 1.92 (1.42 to 2.61) <0.001 +1.1 
Antihypertensive drug treatment 1.63 (1.18 to 2.26) 0.003 +31.5 
    
Women    
Crude model 1.64 (1.37 to 1.97) <0.001  
Progressive adjustment for:    
Sociodemographic variables 1.62 (1.32 to 1.96) <0.001  
Cardiovascular risk factors 1.65 (1.33 to 2.04) <0.001  
Use of healthcare services 1.67 (1.34 to 2.07) <0.001  
Hypertension awareness 1.60 (1.27 to 2.01) <0.001 +10.4 
Antihypertensive drug treatment 1.38 (1.18 to 2.26) 0.008 +36.7 
Logistic regression models were progressively adjusted for sociodemographic variables (age, sex, and 
education level), cardiovascular risk factors (hypertension duration, body mass index, sedentariness, diabetes, 
tobacco smoking, alcohol consumption, and cardiovascular disease), use of healthcare services (physicians 
annual visits), hypertension awareness, and antihypertensive drug treatment. Year 2000-2001 was used as the 
reference category (odds ratio=1). *Percent contribution of the specific healthcare variables (awareness and 
treatment) to the change in hypertension control between the two time periods, after adjustment for the rest of 
the above variables (for calculation, see the Methods section).  
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Table 6. Impact of the Number of Blood Pressure Medications on Change in Blood 
Pressure Control from 2000-2001 to 2008-2010 Among Treated Hypertensive Patients 
Aged ≥60 years in Spain, by Sex. 
 
 Odds ratio 
(95% confidence interval) 
P value % of association 
explained by the number 
of BP medications* 
Total    
Crude model 1.78 (1.52 to 2.08) <0.001  
Models with progressive 
adjustment for: 
   
Sociodemographic variables 1.66 (1.40 to 1.97) <0.001  
Cardiovascular risk factors 1.61 (1.33 to 1.94) <0.001  
Use of healthcare services 1.62 (1.34 to 1.95) <0.001  
Number of BP medications 1.48 (1.20 to 1.80) <0.001 +22.6 
    
Men    
Crude model 2.08 (1.60 to 2.71) <0.001  
Progressive adjustment for:    
Sociodemographic variables 1.84 (1.38 to 2.45) <0.001  
Cardiovascular risk factors 1.77 (1.29 to 2.43) <0.001  
Use of healthcare services 1.79 (1.30 to 2.47) <0.001  
Number of BP medications 1.64 (1.16 to 2.30) 0.001 +19.0 
    
Women    
Crude model 1.67 (1.36 to 2.71) <0.001  
Progressive adjustment for:    
Sociodemographic variables 1.57 (1.27 to 1.94) <0.001  
Cardiovascular risk factors 1.55 (1.22 to 1.96) <0.001  
Use of healthcare services 1.55 (1.22 to 1.97) <0.001  
Number of BP medications 1.42 (1.19 to 1.94) 0.001 +23.6 
BP indicates blood pressure. Logistic regression models were progressively adjusted for 
sociodemographic variables (age, sex, and education level), cardiovascular risk factors (hypertension 
duration, body mass index, sedentariness, diabetes, tobacco smoking, alcohol consumption, and 
cardiovascular disease), use of healthcare services (physicians annual visits), and number of BP 
medications. Year 2000-1 was used as the reference category (odds ratio=1). *Percent contribution of 
the number of BP medications to the change in hypertension control between the two time periods, after 
adjustment for the rest of the above variables (for calculation, see the Methods section). 
 
